Evidence map›Paper›PMID 24583980›Full record

ArticleKidney international2014

β-Lapachone ameliorates murine cisplatin nephrotoxicity: NAD⁺, NQO1, and SIRT1 at the crossroads of metabolism, injury, and inflammation.

Christopher Y Lu

Open access · bronzeAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. β-Lapachone protects against doxorubicin-induced nephrotoxicity via NADNaunyn-Schmiedeberg's archives of pharmacology · 2019
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Christopher Y LuNephrology Division, Department of Internal Medicine, and Graduate Program in Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
The University of Texas Southwestern Medical Center · US

Funding

UT Southwestern O'Brien Kidney Research Core CenterP30DK079328 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI MOE, ORSON W · 2007 to 2021
$16.9M
TLR4 and murine ischemic acute renal failureR01DK069633 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI LU, CHRISTOPHER Y. · 2006 to 2010
$1.6M
Mitochondrial AntiViral Signaling Protein, IRF1, and Ischemic AKIR01DK096251 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI LU, CHRISTOPHER Y. · 2013 to 2013
$159k
NIDDK NIH HHS DK079328NIDDK NIH HHS P30 DK079328NIDDK NIH HHS R01 DK069633NIDDK NIH HHS R01-DK069633NIDDK NIH HHS R01 DK096251
6 · The paper itself

Abstract

The clinical utility of cisplatin is limited by nephrotoxicity. Oh et al. report that β-lapachone prevents this nephrotoxicity but not cisplatin's cytotoxicity for cancers. In addition to its potential clinical importance, the beneficial effect of β-lapachone on cisplatin acute kidney injury may illustrate fundamental processes that ordinarily link alterations in nutrient availability and intracellular reactive oxygen species on the one hand, with inflammation and cell death on the other hand.

Indexed as

Acute Kidney InjuryAnimalsAntineoplastic AgentsCisplatinNADNAD(P)H Dehydrogenase (Quinone)Antineoplastic AgentsCisplatinNADNAD(P)H Dehydrogenase (Quinone)Nqo1 protein, mouse

Identifiers

PMID24583980
PMCPMC3942788
OpenAlexW1982576326

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.